Abbott Q417 Earnings Infographic
Uploaded by
medtechyAbbott Q417 Earnings Infographic
Uploaded by
medtechyQ4 2017 Financial Results SALES WORLDWIDE
+7.7
ON COMPARABLE
%
+42.3 ON REPORTABLE BASIS
%
OPERATIONAL BASIS*
Strong Performance in CORE BUSINESS SEGMENTS 1
SALES ON COMPARABLE OPERATIONAL BASIS
DIAGNOSTICS MEDICAL DEVICES
+ 6.7 % + 9.6%
NUTRITION ESTABLISHED PHARMACEUTICALS
+ 2.0% + 14.0%
FULL-YEAR 2018 GUIDANCE
$
2.80 TO $2.90 ADJUSTED EPS, MIDPOINT REFLECTS 14% GROWTH.2
Life-Changing HEALTH TECHNOLOGY
MORE THAN 20 NEW PRODUCTS LAUNCHED IN 2017
FREESTYLE® LIBRE CONFIRM RX™ INSERTABLE
Launched in the U.S.
CARDIAC MONITOR (ICM)
This revolutionary glucose monitoring system Launched in U.S. & Europe
eliminates routine fingersticks3 for people with The first and only smartphone compatible
diabetes and is now approved for coverage by the ICM helps physicians remotely diagnose
U.S. Center for Medicare & Medicaid Services.4 and treat difficult to detect irregular heartbeats.
ALINITY™ XIENCE SIERRA 5
FDA Clearance for CI-Series Approved in Europe
The game-changing family of diagnostics The newest generation of the company’s
systems stand to change the way labs gold-standard XIENCE everolimus-eluting
work to deliver results that drive better coronary stent system.
patient outcomes.
1
On a GAAP basis, sales increased 51.7% in Diagnostics; 102.2% in Medical Devices; 3% in Nutrition; 17% in Established Pharmaceuticals. 2Full-year 2018 GAAP EPS
guidance of $1.22 to $1.32; Midpoint reflects 535% growth on a GAAP basis. 3Fingersticks are required for treatment decisions when you see Check Blood Glucose symbol,
when symptoms do not match system readings, when you suspect readings may be inaccurate, or when you experience symptoms that may be due to high or low blood
glucose. For more information about FreeStyle Libre system’s indications for use and safety information, please visit: https://freestylelibre.us/safety-information.
4
Coverage includes all Medicare patients with diabetes who use insulin and who meet the eligibility criteria. 5Not available for sale in the United States.
*Comparable operational results are non-GAAP and include the prior year results for St. Jude Medical, and exclude the current year results for Rapid Diagnostics,
acquired on Oct. 3, 2017, the impact of exchange and prior and current year results for divested businesses. For full financial data and reconciliation of non-GAAP
measures, please see our press release dated January 24, 2018.
FORWARD-LOOKING STATEMENTS
Some statements in this news release may be forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995. Abbott cautions that
these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those indicated in the forward-looking
statements. Economic, competitive, governmental, technological and other factors that may affect Abbott’s operations are discussed in Item 1A, “Risk Factors’’ to
our Annual Report on Securities and Exchange Commission Form 10-K for the year ended Dec. 31, 2016, and are incorporated by reference. Abbott undertakes no
obligation to release publicly any revisions to forward-looking statements as a result of subsequent events or developments, except as required by law.
